Sodium bicarbonate: Drug information
Copyright 1978-2018 Lexicomp, Inc. All rights reserved.
(For additional information see "Sodium bicarbonate: Patient drug information" and see "Sodium bicarbonate: Pediatric drug information")

For abbreviations and symbols that may be used in Lexicomp (show table)
Special Alerts
Pfizer Extended Expiration Dates for Emergency Syringe Shortages - updated November 2017

The FDA has alerted health care providers of extended expiration dates for certain injectable drug products manufactured by Hospira (a Pfizer company) which may be used beyond the labeled expiration dates to assist with the ongoing critical shortages of injectable drugs used in critical care. Select lot numbers of atropine sulfate injection, dextrose 50%, epinephrine injection, and sodium bicarbonate are eligible for use beyond the labeled expiration date if they have been and will continue to be stored according to the labeled conditions.

Further information, including specific products, lot numbers, and extended expiration dates, may be found at https://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm563360.htm.

Brand Names: US
  • Neut
Pharmacologic Category
  • Alkalinizing Agent;
  • Antacid;
  • Electrolyte Supplement, Oral;
  • Electrolyte Supplement, Parenteral
Dosing: Adult

Note: 1 mEq NaHCO3 is equivalent to 84 mg; each g of NaHCO3 provides ~12 mEq each of sodium and bicarbonate ions. Each oral tablet (650 mg) contains 7.7 mEq each of sodium and bicarbonate ions.

Cardiac arrest (ACLS 2010): IV: Initial: 1 mEq/kg/dose; repeat doses should be guided by arterial blood gases

Routine use of NaHCO 3 is not recommended. May be considered in the setting of prolonged cardiac arrest only after adequate alveolar ventilation has been established and effective cardiac compressions. Note: In some cardiac arrest situations (eg, metabolic acidosis, hyperkalemia, or tricyclic antidepressant overdose), sodium bicarbonate may be beneficial.

Metabolic acidosis in patients with chronic kidney disease: Oral (off-label): Note: KDIGO guidelines suggest oral replacement when plasma HCO3- concentrations are <22 mEq/L (KDIGO 2013).

Initial: 15.4 to 23.1 mEq/day in divided doses (eg, 650 mg tablet 2 to 3 times daily); titrate to normal serum bicarbonate concentrations (eg, 23 to 29 mEq/L) or up to 5850 mg/day; baking soda may be used as an alternative in patients who cannot take tablets (Chen 2014; KDIGO 2013; Kovesdy 2009; Raphael 2016). Avoid exceeding serum bicarbonate concentrations >32 mEq/L since this has been associated with increased mortality in patients with CKD (Navaneethan 2011).

Metabolic acidosis: IV: Dosage should be based on the following formula if blood gases and pH measurements are available:

HCO3-(mEq) = 0.5 x weight (kg) x [24 - serum HCO3-(mEq/L)] or HCO3-(mEq) = 0.5 x weight (kg) x [desired increase in serum HCO3-(mEq/L)]

Administer 1/2 dose initially, then remaining 1/2 dose over the next 24 hours; monitor pH, serum HCO3-, and clinical status. Note: These equations provide an estimated replacement dose. The underlying cause and degree of acidosis may result in the need for larger or smaller replacement doses. In most cases, the initial goal of therapy is to target a pH of ~7.2 and a plasma bicarbonate level of ~10 mEq/L to prevent overalkalinization. According to the ARDSNet protocol, if pH remains <7.15 after ventilator adjustments, may give NaHCO3 (Brower 2004).

If acid-base status is not available: 2 to 5 mEq/kg IV infusion over 4 to 8 hours; subsequent doses should be based on patient's acid-base status.

Hyperkalemia (ACLS 2010): IV: 50 mEq over 5 minutes (as appropriate, consider methods of enhancing potassium removal/excretion)

Renal tubular acidosis: Oral:

Distal: 0.5 to 2 mEq/kg/day in 4 to 5 divided doses

Proximal: Initial: 5 to 10 mEq/kg/day; maintenance: Increase as required to maintain serum bicarbonate in the normal range

Urine alkalinization: Oral: Initial: 48 mEq (4 g), then 12 to 24 mEq (1 to 2 g) every 4 hours; dose should be titrated to desired urinary pH; doses up to 16 g/day (200 mEq) in patients <60 years and 8 g (100 mEq) in patients >60 years. Administration of 48 mEq (4 g) every 8 hours for a total daily dose of 144 mEq (12 g) has also been shown to achieve a urinary pH of at least 7 after a period of 10 hours in one study of healthy volunteers (Cohen 2013). Note: Intravenous administration is preferred in specific overdoses (eg, salicylate) with a target urinary pH of 7.5 to 8.5 (Levine 2011; Proudfoot 2004).

Antacid: Oral: 325 mg to 2 g 1 to 4 times/day

Neutralize lidocaine with epinephrine dental anesthetic: Neutralizing additive: Mix 10 parts anesthetic (lidocaine with epinephrine) to 1 part 8.4% sodium bicarbonate

Add 0.18 mL sodium bicarbonate to 1.8 mL cartridge of lidocaine 2% with epinephrine 1:50,000 or 1:100,000

Add 2 mL sodium bicarbonate to 20 mL vial of lidocaine 2% with epinephrine 1:100,000

Add 3 mL sodium bicarbonate to 30 mL vial of lidocaine 2% with epinephrine 1:100,000

Add 5 mL sodium bicarbonate to 50 mL vial of lidocaine 2% with epinephrine 1:100,000

Prevention of contrast-induced nephropathy (off-label use): IV infusion: 154 mEq/L sodium bicarbonate in D5W solution: 3 mL/kg/hour for 1 hour immediately before contrast injection, then 1mL/kg/hour during contrast exposure and for 6 hours after procedure (Merten 2004). Some have described a prophylactic strategy based on patient risk for contrast induced nephropathy and procedure type (Goldfarb 2009).

Dosing: Pediatric

(For additional information see "Sodium bicarbonate: Pediatric drug information")

Cardiac arrest (PALS 2010): IV, I.O.: Infants and Children: 1 mEq/kg/dose; repeat doses should be guided by arterial blood gases; children <2 years of age should receive 4.2% (0.5 mEq/mL) solution. Note: If I.O. route is used for administration and is subsequently used to obtain blood samples for acid-base analysis, results will be inaccurate.

Routine use of NaHCO 3 is not recommended. May be considered in the setting of prolonged cardiac arrest only after adequate alveolar ventilation has been established and effective cardiac compressions. Note: In some cardiac arrest situations (eg, metabolic acidosis, hyperkalemia, or tricyclic antidepressant overdose), sodium bicarbonate may be beneficial.

Metabolic acidosis: IV: Infants and Children: Dosage should be based on the following formula if blood gases and pH measurements are available:

HCO3-(mEq) = 0.5 x weight (kg) x [24 - serum HCO3-(mEq/L)] or HCO3-(mEq) = 0.5 x weight (kg) x [desired increase in serum HCO3-(mEq/L)]

Administer 1/2 dose initially, then remaining 1/2 dose over the next 24 hours; monitor pH, serum HCO3-, and clinical status. Note: These equations provide an estimated replacement dose. The underlying cause and degree of acidosis may result in the need for larger or smaller replacement doses. In most cases, the initial goal of therapy is to target a pH of ~7.2 and a plasma bicarbonate level of ~10 mEq/L to prevent overalkalinization.

Note: If acid-base status is not available: Dose for older Children: 2-5 mEq/kg IV infusion over 4-8 hours; subsequent doses should be based on patient's acid-base status.

Chronic renal failure: Oral: Children: Initiate when plasma HCO3- <15 mEq/L: 1-3 mEq/kg/day

Renal tubular acidosis, distal: Oral: Children: 2-3 mEq/kg/day

Renal tubular acidosis, proximal: Children: Initial: 5-10 mEq/kg/day; maintenance: Increase as required to maintain serum bicarbonate in the normal range

Neutralize lidocaine with epinephrine dental anesthetic: Children and Adolescents: Neutralizing additive: Refer to adult dosing.

Urine alkalinization: Oral: Children: 1-10 mEq (84-840 mg)/kg/day in divided doses every 4-6 hours; dose should be titrated to desired urinary pH.

Dosing: Geriatric

Refer to adult dosing.

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Powder, Oral:

Generic: (1 g, 120 g, 454 g, 500 g, 1000 g, 2500 g, 10000 g, 12000 g, 25000 g, 45000 g)

Solution, Intravenous:

Neut: 4% (5 mL)

Generic: 4.2% (5 mL, 10 mL); 7.5% (50 mL); 8.4% (10 mL, 50 mL)

Tablet, Oral:

Generic: 325 mg, 650 mg

Generic Equivalent Available (US)

Yes

Dosage Forms Considerations

Sodium bicarbonate solution 4.2% [42 mg/mL] provides 0.5 mEq/mL each of sodium and bicarbonate

Sodium bicarbonate solution 7.5% [75 mg/mL] provides 0.9 mEq/mL each of sodium and bicarbonate

Sodium bicarbonate solution 8.4% [84 mg/mL] provides 1 mEq/mL each of sodium and bicarbonate

Administration

IV: For IV administration to infants, use the 0.5 mEq/mL solution or dilute the 1 mEq/mL solution 1:1 with sterile water; for direct IV infusion in emergencies, administer slowly (maximum rate in infants: 10 mEq/minute); for infusion, dilute to a maximum concentration of 0.5 mEq/mL in dextrose solution and infuse over 2 hours (maximum rate of administration: 1 mEq/kg/hour).

Vesicant (at concentrations ≥8.4%); ensure proper needle or catheter placement prior to and during IV infusion. Avoid extravasation.

Extravasation management: If extravasation occurs, stop infusion immediately and disconnect (leave needle/cannula in place); gently aspirate extravasated solution (do NOT flush the line); initiate hyaluronidase antidote; remove needle/cannula; apply dry cold compresses (Hurst 2004; Reynolds 2014); elevate extremity.

Hyaluronidase: Intradermal or SubQ: Inject a total of 1 to 1.7 mL (15 units/mL) as five separate 0.2 to 0.3 mL injections (using a 25-gauge needle) into area of extravasation at the leading edge in a clockwise manner (Reynolds 2014).

Oral product should be administered 1 to 3 hours after meals.

Infiltration (dental use; Onpharma): Add specified volume of 8.4% sodium bicarbonate directly with lidocaine and epinephrine injection and mix; use immediately after mixing.

Use

Management of metabolic acidosis; gastric hyperacidity; alkalinization of the urine; treatment of hyperkalemia; management of overdose of certain drugs, including tricyclic antidepressants and aspirin

Neutralizing additive (dental use): Improves onset of analgesia and reduces injection site pain by adjusting lidocaine with epinephrine solution to a more physiologic pH.

Use: Off-Label

Contrast-induced nephropathy (CIN) (prevention)

Adverse Reactions

Frequency not defined.

Cardiovascular: Cardiac failure (exacerbation), edema

Central nervous system: Cerebral hemorrhage

Endocrine & metabolic: Acidosis (intracranial), hypernatremia, hypocalcemia, hypokalemia, metabolic alkalosis, milk-alkali syndrome (especially with renal dysfunction)

Gastrointestinal: Abdominal distention, eructation, flatulence (oral administration)

Neuromuscular & skeletal: Tetany

Respiratory: Pulmonary edema

Contraindications

Alkalosis, hypernatremia, severe pulmonary edema, hypocalcemia, unknown abdominal pain

Neutralizing additive (dental use): Not for use as a systemic alkalizer

Warnings/Precautions

Concerns related to adverse effects:

• Extravasation: Vesicant (at concentrations ≥8.4%); ensure proper catheter or needle position prior to and during infusion. Avoid extravasation (tissue necrosis may occur due to hypertonicity.

Disease-related concerns:

• Cirrhosis: Use with caution in patients with cirrhosis.

• Edema: Use with caution in patients with edema.

• Heart failure: Use with caution in patients with heart failure.

• Peptic ulcer disease: Not to be used in treatment of peptic ulcer disease.

• Renal impairment: Use with caution in patients with renal impairment; may cause sodium retention.

Special populations:

• Elderly: Not the antacid of choice for the elderly because of sodium content and potential for systemic alkalosis.

• Pediatric: Rapid administration in neonates, infants, and children <2 years of age has led to hypernatremia, decreased CSF pressure, and intracranial hemorrhage.

Dosage form specific issues:

• Injection: Use of IV NaHCO3 should be reserved for documented metabolic acidosis and for hyperkalemia-induced cardiac arrest. Routine use in cardiac arrest is not recommended.

Metabolism/Transport Effects

None known.

Drug Interactions

(For additional information: Launch drug interactions program)

Acalabrutinib: Antacids may decrease the serum concentration of Acalabrutinib. Management: Separate administration of acalabrutinib from the administration of any antacids by at least 2 hours in order to minimize the potential for a significant interaction. Risk D: Consider therapy modification

AcetaZOLAMIDE: May enhance the adverse/toxic effect of Sodium Bicarbonate. Specifically, the risk of renal calculus formation may be increased. Risk C: Monitor therapy

Alpha-/Beta-Agonists (Indirect-Acting): Alkalinizing Agents may increase the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting). Risk C: Monitor therapy

Amantadine: Alkalinizing Agents may increase the serum concentration of Amantadine. Risk C: Monitor therapy

Amphetamines: Alkalinizing Agents may decrease the excretion of Amphetamines. Risk D: Consider therapy modification

Antipsychotic Agents (Phenothiazines): Antacids may decrease the absorption of Antipsychotic Agents (Phenothiazines). Risk C: Monitor therapy

Atazanavir: Antacids may decrease the absorption of Atazanavir. Risk D: Consider therapy modification

Bictegravir: Antacids may decrease the serum concentration of Bictegravir. Management: Bictegravir, emtricitabine, and tenofovir alafenamide can be administered while fasting at least 2 hours before antacids. Giving with or 2 hours after antacids is not recommended. Risk D: Consider therapy modification

Bisacodyl: Antacids may diminish the therapeutic effect of Bisacodyl. Antacids may cause the delayed-release bisacodyl tablets to release drug prior to reaching the large intestine. Gastric irritation and/or cramps may occur. Risk D: Consider therapy modification

Bismuth Subcitrate: Antacids may diminish the therapeutic effect of Bismuth Subcitrate. Management: Avoid administration of antacids within 30 minutes of bismuth subcitrate (tripotassium bismuth dicitrate) administration. Risk D: Consider therapy modification

Bosutinib: Antacids may decrease the serum concentration of Bosutinib. Management: Administer antacids more than 2 hours before or after bosutinib. Risk D: Consider therapy modification

Bromperidol: Antacids may decrease the absorption of Bromperidol. Risk C: Monitor therapy

Calcium Polystyrene Sulfonate: Antacids may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. The combined use of these two agents may result in metabolic alkalosis and/or loss of efficacy of the cation exchange resin. Management: To minimize this interaction, consider: a)separating doses by 2 or more hours; b)rectal administration of the exchange resin; or c)alternatives to antacids. Monitor for metabolic alkalosis and attenuation of CPS effects. Avoid magnesium hydroxide. Risk D: Consider therapy modification

Captopril: Antacids may decrease the serum concentration of Captopril. Risk C: Monitor therapy

Cefditoren: Antacids may decrease the serum concentration of Cefditoren. Management: Concomitant use of cefditoren with antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy. If antacid therapy can not be avoided, separate dosing by several hours. Risk D: Consider therapy modification

Cefpodoxime: Antacids may decrease the serum concentration of Cefpodoxime. Risk C: Monitor therapy

Cefuroxime: Antacids may decrease the serum concentration of Cefuroxime. Management: Administer cefuroxime axetil at least 1 hour before or 2 hours after the administration of short-acting antacids. Risk D: Consider therapy modification

Chloroquine: Antacids may decrease the serum concentration of Chloroquine. Management: Separate administration of antacids and chloroquine by at least 4 hours to minimize any potential negative impact of antacids on chloroquine bioavailability. Risk D: Consider therapy modification

Corticosteroids (Oral): Antacids may decrease the bioavailability of Corticosteroids (Oral). Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects. Risk D: Consider therapy modification

Cysteamine (Systemic): Antacids may diminish the therapeutic effect of Cysteamine (Systemic). Risk C: Monitor therapy

Dabigatran Etexilate: Antacids may decrease the serum concentration of Dabigatran Etexilate. Management: Dabigatran etexilate Canadian product labeling recommends avoiding concomitant use with antacids for 24 hours after surgery. In other situations, administer dabigatran etexilate 2 hours prior to antacids. Monitor clinical response to dabigatran therapy. Risk D: Consider therapy modification

Dabrafenib: Antacids may decrease the serum concentration of Dabrafenib. Risk C: Monitor therapy

Dasatinib: Antacids may decrease the absorption of Dasatinib. Risk D: Consider therapy modification

Delavirdine: Antacids may decrease the serum concentration of Delavirdine. Management: Separate doses of delavirdine and antacids by at least 1 hour. Monitor for decreased delavirdine therapeutic effects with this combination. Risk D: Consider therapy modification

Dexmethylphenidate: Antacids may increase the absorption of Dexmethylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption. Risk C: Monitor therapy

Elvitegravir: Antacids may decrease the serum concentration of Elvitegravir. Management: Separate administration of antacids and elvitegravir-containing products by at least 2 hours in order to minimize the risk for an interaction. Risk D: Consider therapy modification

Erlotinib: Antacids may decrease the serum concentration of Erlotinib. Management: Separate the administration of erlotinib and any antacid by several hours in order to minimize the risk of a significant interaction. Risk D: Consider therapy modification

Flecainide: Sodium Bicarbonate may diminish the arrhythmogenic effect of Flecainide. Sodium Bicarbonate may increase the serum concentration of Flecainide. Risk C: Monitor therapy

Fosinopril: Antacids may decrease the serum concentration of Fosinopril. Management: The US and Canadian fosinopril manufacturer labels recommend separating the doses of antacids and fosinopril by 2 hours. Risk D: Consider therapy modification

Gabapentin: Antacids may decrease the serum concentration of Gabapentin. Management: Administer gabapentin at least 2 hours after antacid administration. Monitor patients closely for evidence of reduced response to gabapentin therapy when both of these drugs are being used. Risk D: Consider therapy modification

Gefitinib: Antacids may decrease the serum concentration of Gefitinib. Management: Administer gefitinib at least 6 hours before or after administration of an antacid, and closely monitor clinical response to gefitinib. Risk D: Consider therapy modification

Hyoscyamine: Antacids may decrease the serum concentration of Hyoscyamine. Management: Administer immediate release hyoscyamine before meals and antacids after meals when these agents are given in combination. Risk D: Consider therapy modification

Iron Salts: Antacids may decrease the absorption of Iron Salts. Exceptions: Ferric Carboxymaltose; Ferric Citrate; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose. Risk D: Consider therapy modification

Itraconazole: Antacids may decrease the serum concentration of Itraconazole. Management: Administer itraconazole at least 1 hour after and 2 hours before administration of any antacids. Itraconazole oral suspension may be less sensitive to the effects of decreased gastric acidity. Risk D: Consider therapy modification

Ketoconazole (Systemic): Antacids may decrease the serum concentration of Ketoconazole (Systemic). Management: Administer oral ketoconazole at least 2 hours prior to use of any antacid product. Monitor patients closely for signs of inadequate clinical response to ketoconazole. Risk D: Consider therapy modification

Lanthanum: Antacids may diminish the therapeutic effect of Lanthanum. Risk D: Consider therapy modification

Ledipasvir: Antacids may decrease the serum concentration of Ledipasvir. Management: Separate the administration of ledipasvir and antacids by 4 hours. Risk D: Consider therapy modification

Lithium: Sodium Bicarbonate may increase the excretion of Lithium. Risk C: Monitor therapy

Mecamylamine: Alkalinizing Agents may increase the serum concentration of Mecamylamine. Risk C: Monitor therapy

Memantine: Alkalinizing Agents may increase the serum concentration of Memantine. Risk C: Monitor therapy

Mesalamine: Antacids may diminish the therapeutic effect of Mesalamine. Antacid-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products. Management: Avoid concurrent administration of antacids with sustained-release mesalamine products. Separating antacid and mesalamine administration, and/or using lower antacid doses may be adequate means of avoiding this interaction. Risk D: Consider therapy modification

Methenamine: Antacids may diminish the therapeutic effect of Methenamine. Risk D: Consider therapy modification

Methylphenidate: Antacids may increase the absorption of Methylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption. Risk C: Monitor therapy

Multivitamins/Minerals (with ADEK, Folate, Iron): Antacids may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, antacids may decrease the absorption of orally administered iron. Management: Separate dosing of oral iron-containing multivitamin preparations and antacids by as much time as possible in order to minimize impact on therapeutic efficacy of the iron preparation. Risk D: Consider therapy modification

Neratinib: Antacids may decrease the serum concentration of Neratinib. Specifically, antacids may reduce neratinib absorption. Management: Separate the administration of neratinib and antacids by giving neratinib at least 3 hours after the antacid. Risk D: Consider therapy modification

Nilotinib: Antacids may decrease the serum concentration of Nilotinib. Management: Separate the administration of nilotinib and any antacid by at least 2 hours whenever possible in order to minimize the risk of a significant interaction. Risk D: Consider therapy modification

PAZOPanib: Antacids may decrease the serum concentration of PAZOPanib. Management: Avoid the use of antacids in combination with pazopanib whenever possible. Separate doses by several hours if antacid treatment is considered necessary. The impact of dose separation has not been investigated. Risk D: Consider therapy modification

PenicillAMINE: Antacids may decrease the serum concentration of PenicillAMINE. Risk D: Consider therapy modification

Phosphate Supplements: Antacids may decrease the absorption of Phosphate Supplements. Management: This applies only to oral phosphate administration. Separating administer of oral phosphate supplements from antacid administration by as long as possible may minimize the interaction. Exceptions: Sodium Glycerophosphate Pentahydrate. Risk D: Consider therapy modification

Potassium Phosphate: Antacids may decrease the serum concentration of Potassium Phosphate. Management: Consider separating administration of antacids and oral potassium phosphate by at least 2 hours to decrease risk of a significant interaction. Risk D: Consider therapy modification

QuiNIDine: Antacids may decrease the excretion of QuiNIDine. Risk C: Monitor therapy

QuiNINE: Alkalinizing Agents may increase the serum concentration of QuiNINE. Risk C: Monitor therapy

Rilpivirine: Antacids may decrease the serum concentration of Rilpivirine. Management: Administer antacids at least 2 hours before or 4 hours after rilpivirine. Administer antacids at least 6 hours before or 4 hours after the rilpivirine/dolutegravir combination product. Risk D: Consider therapy modification

Riociguat: Antacids may decrease the serum concentration of Riociguat. Management: Separate the administration of antacids and riociguat by at least 1 hour in order to minimize any potential interaction. Risk D: Consider therapy modification

Rosuvastatin: Antacids may decrease the serum concentration of Rosuvastatin. Risk C: Monitor therapy

Sotalol: Antacids may decrease the serum concentration of Sotalol. Management: Avoid simultaneous administration of sotalol and antacids. Administer antacids 2 hours after sotalol. Risk D: Consider therapy modification

Sulpiride: Antacids may decrease the serum concentration of Sulpiride. Management: Separate administration of antacids and sulpiride by at least 2 hours in order to minimize the impact of antacids on sulpiride absorption. Risk D: Consider therapy modification

Tetracyclines: Antacids may decrease the absorption of Tetracyclines. Management: Separate administration of antacids and oral tetracycline derivatives by several hourse when possible to minimize the extent of this potential interaction. Risk D: Consider therapy modification

Trientine: Antacids may decrease the absorption of Trientine. Management: Separate trientine dosing from other oral drugs (eg, antacids) by at least 1 hour. Monitor for decreased therapeutic effects of trientine if an antacid is initiated/dose increased, or increased effects if an antacid is discontinued/dose decreased. Risk D: Consider therapy modification

Velpatasvir: Antacids may decrease the serum concentration of Velpatasvir. Management: Separate administration of velpatasvir and antacids by at least 4 hours. Risk D: Consider therapy modification

Pregnancy Implications

Animal reproduction studies have not been conducted. Medications used for the treatment of cardiac arrest in pregnancy are the same as in the non-pregnant woman. Doses and indications should follow current Advanced Cardiovascular Life Support guidelines. Appropriate medications should not be withheld due to concerns of fetal teratogenicity (Campbell 2009; Jeejeebhoy [AHA] 2015). Antacids containing sodium bicarbonate should not be used during pregnancy due to their potential to cause metabolic alkalosis and fluid overload (Mahadevan 2007).

Breast-Feeding Considerations

Sodium is found in breast milk (IOM 2004).

Dietary Considerations

Some products may contain sodium. Oral product should be taken 1 to 3 hours after meals.

Mechanism of Action

Dissociates to provide bicarbonate ion which neutralizes hydrogen ion concentration and raises blood and urinary pH

Neutralizing additive (dental use): Increases pH of lidocaine and epinephrine solution to improve tolerability and increase tissue uptake

Pharmacodynamics/Kinetics

Onset of action: Oral: 15 minutes; IV: Rapid

Duration: Oral: 1 to 3 hours; IV: 8 to 10 minutes

Absorption: Oral: Well absorbed

Excretion: Urine (<1%)

Pricing: US

Solution (Neut Intravenous)

4% (5 mL): $9.16

Solution (Sodium Bicarbonate Intravenous)

4.2% (5 mL): $3.06

7.5% (50 mL): $3.42

8.4% (50 mL): $10.82

Tablets (Sodium Bicarbonate Oral)

325 mg (1000): $28.28

650 mg (1000): $13.99

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Brand Names: International
  • Betsol "Z" (MX);
  • Natrium bicarbonicum (PL);
  • Sodibic (AU);
  • Solunate (PH)
Use of UpToDate is subject to the Subscription and License Agreement.

REFERENCES

  1. Adrogué HJ and Madias NE, "Management of Life-Threatening Acid-Base Disorders. Second of Two Parts," N Engl J Med, 1998, 338(2):107-11. [PubMed 9420343]
  2. Brar SS, Hiremath S, Dangas G, Mehran R, Brar SK, Leon MB. Sodium bicarbonate for the prevention of contrast induced-acute kidney injury: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2009;4(10):1584-1592. [PubMed 19713291]
  3. Brierley J, Carcillo JA, Choong K, et al, “Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock: 2007 Update from the American College of Critical Care Medicine,” Crit Care Med, 2009, 37(2):666-88. [PubMed 19325359]
  4. Briguori C, Airoldi F, D’Andrea D, et al, “Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL). A Randomized Comparison of 3 Preventive Strategies,” Circulation, 2007, 115(10):1211-17. [PubMed 17309916]
  5. Brower RG, Lanken PN, MacIntyre N, National Heart, Lung, and Blood Institute ARDS Clinical Trials Network, et al. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med. 2004;351(4):327-336. [PubMed 15269312]
  6. Campbell TA and Sanson TG, "Cardiac Arrest and Pregnancy," J Emerg Trauma Shock, 2009, 2(1):34-42. [PubMed 19561954]
  7. Chen W, Abramowitz MK. Treatment of metabolic acidosis in patients with CKD. Am J Kidney Dis. 2014;63(2):311-317. [PubMed 23932089]
  8. Del Beccaro MA and Robertson WO, “Baking Soda Poisoning,” Vet Hum Toxicol, 1988, 30(2):164-5. [PubMed 2837866]
  9. Field JM, Hazinski MF, Sayre MR, et al, “Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,” Circulation, 2010, 122 (Suppl 3):640-56.
  10. Forsythe SM and Schmidt GA, “Sodium Bicarbonate for the Treatment of Lactic Acidosis,” Chest, 2000, 117(1):260-7. [PubMed 10631227]
  11. Goldfarb S, McCullough PA, McDermott J, Gay SB. Contrast-induced acute kidney injury: specialty-specific protocols for interventional radiology, diagnostic computed tomography radiology, and interventional cardiology. Mayo Clin Proc. 2009;84(2):170-179. [PubMed 19181651]
  12. Hadaway L, "Infiltration and extravasation," Am J Nurs, 2007, 107(8):64-72. [PubMed 17667395]
  13. Hurst S, McMillan M, "Innovative solutions in critical care units: extravasation guidelines," Dimens Crit Care Nurs, 2004, 23(3):125-128. [PubMed 15192356]
  14. IOM (Institute of Medicine), Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate, Washington, DC: National Academy Press, 2004.
  15. Jeejeebhoy FM, Zelop CM, Lipman S, et al; American Heart Association Emergency Cardiovascular Care Committee, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Cardiovascular Diseases in the Young, and Council on Clinical Cardiology. Cardiac Arrest in Pregnancy: A Scientific Statement From the American Heart Association. Circulation. 2015;132(18):1747-1773. doi: 10.1161/CIR.0000000000000300. [PubMed 26443610]
  16. Kleinman ME, Chameides L, Schexnayder SM, et al, “Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,” Circulation, 2010, 122(18 Suppl 3):876-908. [PubMed 20956230]
  17. Kidney Disease Improving Global Outcomes (KDIGO). 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Available at http://www.kidney-international.org.
  18. Kidney Disease Imporiving Global Outcomes (KDIGO) clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012a;2(suppl 1):1-138. http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO%20AKI%20Guideline.pdf. Published March 2012. Accessed March 15, 2017.KDIGO.2012.1
  19. Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Association of serum bicarbonate levels with mortality in patients with non-dialysis-dependent CKD. Nephrol Dial Transplant. 2009;24(4):1232-1237. [PubMed 19015169]
  20. Levin T, “What This Patient Didn't Need: A Dose of Salts,” Hosp Pract (Off Ed), 1983, 18(7):95-8.
  21. Linford SM and James HD, “Sodium Bicarbonate Abuse: A Case Report,” Br J Psychiatry, 1986, 149:502-3. [PubMed 3028562]
  22. MacCara ME, “Extravasation - A Hazard of Intravenous Therapy,” Drug Intell Clin Pharm, 1983, 17:713. [PubMed 6628223]
  23. Mahadevan U and Kane S, "American Gastroenterological Association Institute Medical Position Statement on the Use of Gastrointestinal Medications in Pregnancy," Gastroenterology, 2006, 131(1):278-82. [PubMed 16831610]
  24. Mahadevan U, "Gastrointestinal Medications in Pregnancy," Best Pract Res Clin Gastroenterol, 2007, 21(5):849-77. [PubMed 17889812]
  25. Merten GJ, Burgess WP, Gray LV, et al, “Prevention of Contrast-Induced Nephropathy With Sodium Bicarbonate: A Randomized Controlled Trial,” JAMA, 2004, 291(19):2328-34. [PubMed 15150204]
  26. Narins RG and Cohen JJ, “Bicarbonate Therapy for Organic Acidosis: The Case for Its Continued Use,” Ann Intern Med, 1987, 106(4):615-8. [PubMed 3103511]
  27. Navaneethan SD, Schold JD, Arrigain S, et al. Serum bicarbonate and mortality in stage 3 and stage 4 chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(10):2395-2402. [PubMed 21885787]
  28. Neumar RW, Otto CW, Link MS, et al, “Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,” Circulation, 2010, 122(18 Suppl 3):729-67.
  29. Nichols MH, Wason S, Gonzalez Del Rey J, et al, “Baking Soda: A Potentially Fatal Home Remedy,” Pediatr Emerg Care, 1995, 11(2):109-11. [PubMed 7596870]
  30. Ozcan EE, Guneri S, Akdeniz B, et al. Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radiocontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial. Am Heart J. 2007;154(3):539-544. [PubMed 17719303]
  31. Perrone J and Hoffman RS, “Profound Metabolic Alkalosis With Respiratory Compensation From Sodium Bicarbonate Ingestion,” J Toxicol Clin Toxicol, 1995, 33(5):547.
  32. Raphael KL. Approach to the Treatment of Chronic Metabolic Acidosis in CKD. Am J Kidney Dis. 2016;67(4):696-702.
  33. Reynolds PM, MacLaren R, Mueller SW, Fish DN, Kiser TH. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. Pharmacotherapy. 2014;34(6):617-632. [PubMed 24420913]
  34. Stacul F, van der Molen AJ, Reimer P, et al; Contrast Media Safety Committee of European Society Urogenital Radiology (ESUR). Contrast induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol. 2011;21(12):2527-2541. [PubMed 21866433]
  35. Stork CM, Redd JT, Fine K, et al, “Propoxyphene-Induced Wide QRS Complex Dysrhythmia Responsive to Sodium Bicarbonate - A Case Report,” J Toxicol Clin Toxicol, 1995, 33(2):179-83. [PubMed 7897759]
  36. Vanden Hoek TL, Morrison LJ, Shuster M, et al, “Part 12: Cardiac Arrest in Special Situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,” Circulation, 2010, 122(18 Suppl 3):829-61. [PubMed 20956228]
  37. Wax PM and Hoffman RS, “Sodium Bicarbonate in Contemporary Management in Critical Care,” 1991, 1(3):81-108.
  38. Zoungas S, Ninomiya T, Huxley R, et al. Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy. Ann Intern Med. 2009;151(9):631-638. [PubMed 19884624]
Topic 9928 Version 194.0